Trademarkia Logo

Canada

C$
Trademark Search in Canada
Neuracthel

View On IC.GC.CA

Neuracthel
APPROVED

on 5 Feb 2025

Last Applicant/ Owned by

Clinuvel Europe Ltd

Earlsfort Terrace 10Dublin 2 D02 T380

IE

Serial Number

2208295 filed on 7th Apr 2022

Correspondent Address

MARKS & CLERK

33 Yonge Street, Suite 300Toronto

ONTARIO

CA

M5E1G4

Neuracthel

Trademark usage description

non-medicated cosmetics; cosmetics for protecting against light and uv; cosmetics, namely cosmetic products as leave-on, lotions, cremes, ointments an Read More

Classification Information

Class [003]
Non-medicated cosmetics; cosmetics for protecting against light and UV; cosmetics, namely cosmetic products as leave-on, lotions, cremes, ointments and other formulations as well as cosmetic products for topical use; non-medicated preparations for protecting the skin against light and UV; non-medicated skin photoprotection preparations; sun care preparations for cosmetic use; sun-tanning preparations (cosmetics); suntan lotions (cosmetics); suntan oils (cosmetics); tanning gels (cosmetics); cosmetic preparations for skin care containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; cosmetics for tanning the skin containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; cosmetic preparations for tanning the skin without sunlight containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; sun protection preparations; cosmetic preparations for protecting the skin from the sun's rays; cosmetics for protecting the skin from sunburn; sun protecting creams (cosmetics); sun barriers (cosmetics); sun block (cosmetics); sun blocking preparations (cosmetics); sun-block lotions; sun blocking oils (cosmetics); SPF sun block sprays; sun protectors for lips; sun blocking lipsticks (cosmetics); sunscreens; waterproof sunscreen; water-resistant sunscreen; sunscreen preparations; sunscreen creams; sunscreen lotions; sunscreen sticks; cosmetic foams containing sunscreens; preparations for protecting the hair from the sun; non-medicated preparations for the relief of sunburn; non-medicated compounds for skin care after exposure to the sun's rays.

Classification kind code

11

Class [005]
Pharmaceuticals for the prevention and treatment of viral skin infections namely, herpes, shingles and chickenpox, metabolic diseases and disorders, namely, Erythropoietic Protoporphyria (EPP), Variegate Porphyria, West syndrome, diabetes, gout, arthritis, anemia, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, genetic diseases and disorders, musculoskeletal diseases and disorders, ophthalmic diseases and disorders, cardiovascular diseases and disorders, cerebrovascular diseases and disorders, cardiopulmonary diseases and disorders, genitourinary diseases and disorders, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases, oncological diseases and disorders, hepatological diseases and disorders, respiratory diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, central nervous system disorders, namely, stroke, Multiple Sclerosis, traumatic brain injury and vascular disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, bacterial skin infections, eczema, acne, rosacea, ichthyosis, vitiligo, urticaria, alopecia areata, bacterial skin infections and fungal skin infections, psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders, immune system diseases and disorders, namely, autoimmune diseases and disorders, stress and blood pressure related diseases and disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical products for endocrine, neuroendocrine, systemic, inflammatory, and acute disorders such as sepsis, shock, haemorrhagic shock, acute bleeding disorders, and chronic disorders requiring prevention, curative or palliative treatment where no other treatments are effective or safe; pharmaceutical preparations for the prevention and treatment of muscle spasms, tremors, pain and of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases and infantile spasms; pharmaceutical preparations, namely, adrenocorticotropic hormones for medical purposes; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke); pharmaceutical preparations for the prevention and treatment of arterial ischemic strokes; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the prevention and treatment of cardiovascular and cerebrovascular diseases; cardiovascular drugs for use in treating hypertension; cardiovascular preparations for treating cardiometabolic conditions, namely, heart attacks, strokes, diabetes, insulin resistance and non-alcoholic fatty liver disease; cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; cardiovascular agents for treating cardiomyopathy and congenital heart disease; cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; sun tanning preparations for pharmaceutical purposes containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; pharmaceutical preparations for skin care conditions being acne, rosacea, ichthyosis, vitiligo, leukoderma, urticaria, alopecia areata, actinic keratosis, dermatitis, and skin pigmentation diseases; pharmaceutical preparations for treating skin disorders, namely, heat rashes, sunburn, hyperpigmentation, hypopigmentation, haemorrhoids, chafed skin, minor burns, bed sores, abrasions, shingles, chapped lips, incontinent rashes, poison ivy and oak, rectal itching, fever blisters, wounds, blisters, cuts and sores; dermatological preparations for protecting the skin against sunlight and artificial light, namely medicated sunscreen for medical use; dermatological pharmaceutical substances for the treatment of dermatological diseases and disorders, namely, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; dermatological pharmaceutical products, namely medicated sun block; medicinal creams for the protection of the skin, namely, for the prevention and repair of DNA damage and photodamage; skin care creams for medical use, namely, medicated creams for hydrating the skin; skin care preparations for medical use, namely, medicated dermatological preparations for protecting the skin against sunlight and artificial light, namely, creams, lotions, serums, oils and gels; medicated skin creams and lotions for preventing and treating sunburn; medicated creams for application after exposure to the sun, namely, medicated protective and moisturizing creams and ointments for sunburn; pharmaceutical medicated skin care and toiletry preparations, namely, oils, ointments, serums, salves, balms, creams, lotions, gels, toners, cleaners, peels, and roll-on sticks; preparations for cleansing the skin for medical use; chemical and biological preparations, substances, reagents and compounds for medical purposes, namely a drug delivery system containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; pharmaceutical formulations, namely, afamelanotide, in liquid and gel form; pharmaceutical implants for the prevention and treatment of neurological, endocrinological, neuroendocrinological, degenerative, central nervous system, and dermatological disorders; subcutaneous drug delivery implants containing afamelanotide for the treatment of dermatitis, erythropoietic protoporphyria, skin pigmentation diseases, hyperpigmentation, hypopigmentation, vitiligo, leukoderma, psoriasis, heat rashes, and sunburn; implantable medicines, namely, subcutaneous drug delivery implants for the prevention and treatment of muscle spasms, tremors, and multiple sclerosis; implantable medicines containing afamelanotide, namely, subcutaneous pharmaceutical implants containing afamelanotide for the prevention of phototoxicity.

Classification kind code

11

Class [010]
Implantable drug delivery devices; apparatus for drug administration, namely, drug delivery catheters and cannulas; devices for use in the administration of pharmaceuticals, namely, vascular access ports; controlled rate release apparatus for dispensing pharmaceutical substances, namely, drug delivery pumps; medical fluid injectors, namely, injectors for medical purposes; injection syringes; medical syringes; implantable subcutaneous drug delivery devices.

Classification kind code

11

Mark Details

Serial Number

2208295

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 48
on 20th Jan 2025		Agent Changed
Submitted for opposition 22
on 6th Dec 2023		Search Recorded
Submitted for opposition 20
on 6th Dec 2023		Examiner's First Report
Submitted for opposition 223
on 6th Dec 2023		Total Provisional Refusal
Submitted for opposition 256
on 10th Jul 2023		Notification of Possible Opposition Sent
Submitted for opposition 257
on 8th Sept 2022		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 7th Sept 2022		Created
Submitted for opposition 31
on 7th Sept 2022		Formalized
Submitted for opposition 30
on 7th Apr 2022		Filed
Submitted for opposition 228
on 7th Apr 2022		International Registration